Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 14751 | 17.9316 |
09:34 ET | 7305 | 17.91 |
09:36 ET | 5284 | 17.885 |
09:38 ET | 14599 | 18.005 |
09:39 ET | 2397 | 18.03 |
09:41 ET | 2804 | 17.9705 |
09:43 ET | 7738 | 17.925 |
09:45 ET | 8040 | 17.845 |
09:48 ET | 6317 | 17.932 |
09:50 ET | 3232 | 17.875 |
09:52 ET | 9256 | 17.87 |
09:54 ET | 1405 | 17.88 |
09:56 ET | 22099 | 17.89 |
09:57 ET | 3006 | 17.9 |
09:59 ET | 13808 | 17.93 |
10:01 ET | 2300 | 17.95 |
10:03 ET | 1850 | 17.9599 |
10:06 ET | 3122 | 17.8937 |
10:08 ET | 4711 | 17.89 |
10:10 ET | 5719 | 17.925 |
10:12 ET | 5900 | 17.91 |
10:14 ET | 3397 | 17.87 |
10:15 ET | 10170 | 17.94 |
10:17 ET | 2120 | 17.96 |
10:19 ET | 4395 | 17.98 |
10:21 ET | 1904 | 17.95 |
10:24 ET | 7215 | 17.91 |
10:26 ET | 6806 | 17.92 |
10:28 ET | 4340 | 17.88 |
10:30 ET | 13956 | 17.87 |
10:32 ET | 24448 | 17.9 |
10:33 ET | 3879 | 17.9 |
10:35 ET | 7485 | 17.88 |
10:37 ET | 12328 | 17.89 |
10:39 ET | 7957 | 17.865 |
10:42 ET | 6144 | 17.96 |
10:44 ET | 1800 | 17.9699 |
10:46 ET | 928 | 18 |
10:48 ET | 4250 | 18.01 |
10:50 ET | 4709 | 17.95 |
10:51 ET | 2444 | 17.95 |
10:53 ET | 2134 | 17.92 |
10:55 ET | 9910 | 17.93 |
10:57 ET | 1568 | 17.91 |
11:00 ET | 2171 | 17.92 |
11:02 ET | 200 | 17.9 |
11:04 ET | 13470 | 17.89 |
11:06 ET | 8908 | 17.875 |
11:08 ET | 24436 | 17.915 |
11:09 ET | 9284 | 17.865 |
11:11 ET | 35128 | 17.88 |
11:13 ET | 8329 | 17.855 |
11:15 ET | 9835 | 17.9101 |
11:18 ET | 5601 | 17.8907 |
11:20 ET | 7717 | 17.8905 |
11:22 ET | 21518 | 17.905 |
11:24 ET | 18569 | 17.95 |
11:26 ET | 2697 | 17.94 |
11:27 ET | 2141 | 17.93 |
11:29 ET | 6616 | 17.97 |
11:31 ET | 500 | 17.96 |
11:33 ET | 12445 | 17.941 |
11:36 ET | 1696 | 17.96 |
11:38 ET | 1200 | 17.94 |
11:40 ET | 808 | 17.93 |
11:42 ET | 1537 | 17.93 |
11:44 ET | 4043 | 17.935 |
11:45 ET | 1600 | 17.9 |
11:47 ET | 1458 | 17.91 |
11:49 ET | 1900 | 17.91 |
11:51 ET | 1203 | 17.93 |
11:54 ET | 3551 | 17.92 |
11:56 ET | 13706 | 17.911 |
11:58 ET | 26630 | 17.88 |
12:00 ET | 9494 | 17.89 |
12:02 ET | 8198 | 17.92 |
12:03 ET | 5725 | 17.935 |
12:05 ET | 248 | 17.93 |
12:07 ET | 3396 | 17.94 |
12:09 ET | 7098 | 17.93 |
12:12 ET | 2571 | 17.9226 |
12:14 ET | 1938 | 17.915 |
12:16 ET | 7812 | 17.8976 |
12:18 ET | 4998 | 17.89 |
12:20 ET | 15091 | 17.94 |
12:21 ET | 1948 | 17.91 |
12:23 ET | 700 | 17.91 |
12:25 ET | 1016 | 17.94 |
12:27 ET | 2170 | 17.93 |
12:30 ET | 1463 | 17.9327 |
12:32 ET | 500 | 17.95 |
12:34 ET | 8096 | 17.93 |
12:36 ET | 3202 | 17.9599 |
12:38 ET | 1152 | 17.93 |
12:39 ET | 5177 | 17.874 |
12:41 ET | 18581 | 17.86 |
12:43 ET | 34696 | 17.805 |
12:45 ET | 1695 | 17.84 |
12:48 ET | 1458 | 17.85 |
12:50 ET | 4490 | 17.82 |
12:52 ET | 5623 | 17.79 |
12:54 ET | 2610 | 17.775 |
12:56 ET | 2920 | 17.78 |
12:57 ET | 4000 | 17.7801 |
12:59 ET | 8203 | 17.7648 |
01:01 ET | 14729 | 17.73 |
01:03 ET | 6866 | 17.71 |
01:06 ET | 9693 | 17.74 |
01:08 ET | 4037 | 17.765 |
01:10 ET | 2267 | 17.79 |
01:12 ET | 208 | 17.79 |
01:14 ET | 1450 | 17.78 |
01:15 ET | 1000 | 17.8 |
01:17 ET | 550 | 17.785 |
01:19 ET | 300 | 17.8 |
01:21 ET | 3322 | 17.75 |
01:24 ET | 700 | 17.75 |
01:26 ET | 3007 | 17.76 |
01:28 ET | 1307 | 17.74 |
01:30 ET | 4684 | 17.73 |
01:32 ET | 9853 | 17.7 |
01:33 ET | 8653 | 17.69 |
01:35 ET | 8915 | 17.67 |
01:37 ET | 5582 | 17.6663 |
01:39 ET | 13626 | 17.62 |
01:42 ET | 9640 | 17.6 |
01:44 ET | 5621 | 17.62 |
01:46 ET | 1799 | 17.6 |
01:48 ET | 918 | 17.6 |
01:50 ET | 3199 | 17.6174 |
01:51 ET | 1728 | 17.6 |
01:53 ET | 3064 | 17.58 |
01:55 ET | 8442 | 17.58 |
01:57 ET | 2161 | 17.58 |
02:00 ET | 1125 | 17.56 |
02:02 ET | 9138 | 17.62 |
02:04 ET | 3369 | 17.615 |
02:06 ET | 2312 | 17.63 |
02:08 ET | 1378 | 17.62 |
02:09 ET | 2313 | 17.63 |
02:11 ET | 3600 | 17.67 |
02:13 ET | 1447 | 17.685 |
02:15 ET | 2214 | 17.7 |
02:18 ET | 5800 | 17.7 |
02:20 ET | 11929 | 17.71 |
02:22 ET | 200 | 17.7 |
02:24 ET | 6499 | 17.71 |
02:26 ET | 323 | 17.701 |
02:27 ET | 2255 | 17.71 |
02:29 ET | 254 | 17.69 |
02:31 ET | 2158 | 17.66 |
02:33 ET | 551 | 17.6645 |
02:36 ET | 800 | 17.66 |
02:38 ET | 3347 | 17.66 |
02:40 ET | 1200 | 17.66 |
02:42 ET | 5068 | 17.67 |
02:44 ET | 605 | 17.6795 |
02:45 ET | 2200 | 17.67 |
02:47 ET | 3850 | 17.66 |
02:49 ET | 17957 | 17.61 |
02:51 ET | 1800 | 17.6 |
02:54 ET | 2525 | 17.61 |
02:56 ET | 1894 | 17.6 |
02:58 ET | 1795 | 17.58 |
03:00 ET | 3620 | 17.59 |
03:02 ET | 38534 | 17.55 |
03:03 ET | 8331 | 17.54 |
03:05 ET | 3452 | 17.55 |
03:07 ET | 1423 | 17.57 |
03:09 ET | 4199 | 17.5988 |
03:12 ET | 2559 | 17.57 |
03:14 ET | 1900 | 17.56 |
03:16 ET | 17224 | 17.5231 |
03:18 ET | 1100 | 17.52 |
03:20 ET | 11559 | 17.49 |
03:21 ET | 8762 | 17.48 |
03:23 ET | 9074 | 17.45 |
03:25 ET | 11752 | 17.46 |
03:27 ET | 11725 | 17.5 |
03:30 ET | 3505 | 17.5053 |
03:32 ET | 23033 | 17.45 |
03:34 ET | 3507 | 17.45 |
03:36 ET | 5397 | 17.48 |
03:38 ET | 3448 | 17.5 |
03:39 ET | 3244 | 17.49 |
03:41 ET | 6488 | 17.49 |
03:43 ET | 4095 | 17.485 |
03:45 ET | 7986 | 17.465 |
03:48 ET | 11388 | 17.4875 |
03:50 ET | 9232 | 17.49 |
03:52 ET | 39038 | 17.66 |
03:54 ET | 17907 | 17.63 |
03:56 ET | 50963 | 17.83 |
03:57 ET | 47871 | 17.78 |
03:59 ET | 70993 | 17.79 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 2.7B | 80.7x | --- |
Twist Bioscience Corp | 2.9B | -14.7x | --- |
ADMA Biologics Inc | 2.6B | -548.0x | --- |
MorphoSys AG | 2.7B | -5.4x | --- |
Arrowhead Pharmaceuticals Inc | 3.2B | -6.1x | --- |
Vericel Corp | 2.2B | 4,799.2x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.23 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 80.7x |
Price/Sales (TTM) | 9.5 |
Price/Cash Flow (TTM) | 66.5x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.